Overview
DIAGENS-B (2526)
Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Softwar...
- Open
- 87.600
- High
- 114.500
- Low
- 86.000
- Prev. Close
- 85.000
- Volume
- 1.99M
- Turnover
- 207.59M
- Avg Price
- 104.278
- Bid/Ask Ratio
- -37.50%
- Amplitude
- 33.53%
- 52wk High
- 765.500
- Volume Ratio
- 30.89
- Turnover Ratio
- 2.24%
- 52wk Low
- 82.000
- HK Mkt Cap
- 9.29B
- Market CapHKD
- 9.29B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.58
- EPSDynamic
- -1.45
- EPSStatic
- --
- BVPS
- 10.04
- P/B
- 10.41
- HK Shares
- 88.88M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 88.88M
- Min lot size
- 50
- Currency
- HKD
DIAGENS-B Analyst Rating
View moreForecast & Rating
Nov 2, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Diagens-B (2526.HK) rebounded 22.9% to HK$104.5 versus a prior close of HK$85.0, opening at HK$87.6, dipping to HK$93.3 early before spiking to HK$114.5 at 15:26 and closing near the day's midpoint, on 1.97 million shares worth about HK$206 million; the triggers were progress on its iMed-6.0 medical-imaging models, disclosure that its chest-and-abdominal CT analysis now covers 509 imaging targets, and a medical-imaging AI partnership with the Guangxi laboratory. Fundamentals cut both ways: Q2 revenue rose 27.6% year on year to HK$62.8 million, yet the net loss widened to HK$32.3 million at a -51.4% net margin. The shares still trade below the MA20 of HK$146.56 and MA60 of HK$316.12, down 50.1% year to date and 86.4% below the HK$765.5 52-week high, though 27.4% above the HK$82.0 low, with PB at 10.41 against a PE of -66.3. Though the Hang Seng added only 0.84% at midday, the stock's intraday range exceeded 30%, pointing more to low-level positioning flows.
- Nov, 13
Diagens-B (2526.HK) spiked and then faded to close at HK$85.00, down 8.6%, as the bounce off the prior session's 52-week low of HK$82.00 failed: the stock reached HK$94.45 in the morning session before sliding to HK$82.25 at 15:25 BJ, a drawdown of more than 13% from the intraday high. Q2 2026 revenue grew 27.58% year on year to HK$62.77 million, yet the net loss widened to HK$32.27 million with a -51.41% net margin and EPS of -HK$0.3798, leaving the shares at a PE of -53.93 and PB of 8.47. Disclosures on the iMed-6.0 imaging models, the extension of chest and abdominal CT analysis to 509 imaging targets and a partnership with Guangxi Laboratory did not reverse the drift. The stock is down 59.45% year to date, 88.9% below its 52-week high of HK$765.5, and trades well under its MA20 of 152.94 and MA60 of 321.4. Though it sits only 3.66% above the 52-week low, volume of 204,200 shares and a 0.23% turnover rate point to thin liquidity.
- Nov, 12
Diagens-B reversed early losses but faded again in the afternoon, last at HK$93.00 against a HK$91.60 prior close, up 1.5%, after touching HK$86.00 at 09:37 BJ, rallying to HK$94.30 by 11:46 and then easing to roughly HK$90.50. The swing tracks a choppy news tape: the stock had just printed a fresh 52-week low, yet also logged single-day jumps of 14% and 10%, with the medical-imaging AI theme doing the work through a tie-up with the Guangxi laboratory on imaging AI and a state science award for a Chinese medical AI model. Fundamentals show revenue growth against widening losses: Q2 revenue HK$62.8m, up 27.58% year on year, with a net loss of HK$32.3m and a -51.41% net margin. The price remains far below its averages, down 55.63% year to date and 87.85% below the 52-week high of HK$765.50, versus MA20 of HK$159.57 and MA60 of HK$325.50. Though turnover of HK$30.8m and a 0.38% turnover rate point to thin participation.
- Nov, 11
Diagens-B reversed intraday to close down 3.3% at HK$91.60, having spiked to HK$98.65 at 14:34 in the afternoon session before sliding to HK$90.50 by 15:12, an intraday range of more than 8% on HK$37.4 million turnover and a thin 0.45% turnover rate. The medical-imaging AI tie-up with the Guangxi laboratory and a single-day jump of more than 10% both failed to hold, with last week's 29.18% slide and a fresh test of the 52-week low at HK$89.80 leaving the rebound unfinished. Q2 revenue rose 27.58% year on year to HK$62.77 million, yet the net loss stayed at HK$32.27 million with a -51.41% net margin and a HK$0.3798 per-share loss; the stock trades at -58.11x PE and 9.12x PB. At HK$91.60 it sits 88.03% below the HK$765.50 52-week high, down 56.30% year to date, and well under MA20 of HK$165.89 and MA60 of HK$330.06. Though a grant of 778,962 share awards to 23 employees remains in progress.
- Nov, 10
A strategic cooperation pact with Yongjiang Laboratory to demonstrate large medical imaging models in Guangxi failed to hold the stock up, and the shares gapped to HK$105.00 before reversing to close at HK$95.00, down 4.95%, with an afternoon slide to HK$90.35 at 14:10 BJ and an intraday range above 15%. The move extends a weak stretch in which the stock fell roughly 29% over the prior week and printed a 52-week low of HK$89.80. Fundamentals cut both ways: Q2 revenue rose 27.58% year on year to HK$62.77 million, yet the net loss reached HK$32.27 million on a -51.41% net margin, against a 9.46x price-to-book. The price sits 54.68% lower year to date, 87.59% below the 52-week high of HK$765.50 and well under its MA20 of 172.72 and MA60 of 334.78; Huatai Securities initiated coverage with a HK$296.13 target, though spot remains far from that level.
News
Market Movers · Diagens surges 13%
Weekly Review · Weekly Recap | DIAGENS-B -14.96%, hits 52-week low
Market Movers · Diagens drops 8% to 52-week low
Tip Ranks · Diagens Reports Progress in iMed-6.0 Medical Imaging Models
prnewswire · DIAGENS Leads Medical AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets
Market Movers · Diagens hits 52-week low
